RxDoctor Payments Data

Monica Kaul

Nephrology · Huntington Station, NYNPI 1316007941

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.3% of the total across 9 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Calliditas Therapeutics US Inc. at 24.5% of the total. 2025 is the largest year on record at $260, more than ten times the $15 reported in 2020. That places this record below the midpoint for nephrology clinicians in NY, where the typical reported total is $564.

$566in general payments, 2019–2025

Across 9 payments — averaging $62.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Calliditas Therapeutics US Inc.$139
  • Travere Therapeutics, Inc.$125
  • Mallinckrodt Hospital Products Inc.$118
  • Ardelyx, Inc.$116
  • AstraZeneca$50
  • Boehringer Ingelheim$19

What the payments were for

  • Food & beverage$53494%
  • Education$326%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$566 in reported general payments places this provider in the 50th percentile of 935 nephrology providers in New York.

See all nephrology providers in New York →

Medicare billing

Part B allowed, 2024
$238,604
Medicare patients
460
Services billed
1,643

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol19$32,015
KerendiaFinerenone15$20,279
LokelmaSodium Zirconium Cyclosilicate13$17,979
Sevelamer Carbonate16$5,069
Calcium Acetate13$1,340
Calcitriol50$1,098
Potassium Citrate ErPotassium Citrate13$793
Valsartan15$493
Furosemide45$441
Losartan Potassium43$405
Doxazosin Mesylate12$263
Amlodipine Besylate20$155
Lisinopril15$147
Atorvastatin Calcium13$53

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$50$49,99432 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 935 nephrology providers in New York.

Other nephrology in Huntington Station

See the full list for New York →

Where these figures come from

Is this you, or does something look wrong? →